Biotechnology

Biovica Appoints Maria Ekdahl as New Chief Financial Officer

July 7, 2026 7:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financial Officer (CFO). Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical company, Infant Bacterial Therapeutics AB (IBT), and will join Biovica on October 14, 2026. Ekdahl has broad experience across...

Read more

Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026

July 7, 2026 6:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing high-potential drug candidates for diseases with significant unmet medical needs through a disciplined pharmaceutical development platform and focused subsidiary companies, today announced that it has filed its Notice of Annual General and Special Meeting and Management Information Circular (the "Circular") for its upcoming Annual General...

Read more

Biovica Expands Master Services Agreement with a Current Customer, a Leading Global Pharmaceutical Company, to Support Next-Generation Oncology Development

July 7, 2026 4:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announces an expanded Master Services Agreement with a current customer, one of the world's leading pharmaceutical companies, which has a broad and active oncology pipeline. Under the agreement, Biovica will provide DiviTum® TKa testing services for oncology development programs. The agreement establishes an...

Read more

Vicore Pharma to Participate in the Leerink Therapeutics Forum

July 7, 2026 2:20 AM

Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Leerink Therapeutics Forum. Location: Boston Harbor Hotel, Boston, Mass. Format: 1×1 meetings Date: Tuesday, July 14, 2026 Participant: Ahmed Mousa, CEO For more information, please...

Read more

Guide to Avoid Pitfalls in Primary Cell Procurement Released! Cloud-Clone Corp. Unveils Buying Guide for Novice Researchers to Boost Research Efficiency

July 6, 2026 4:00 PM

In the fields of life sciences and pharmaceutical R&D, primary cells retain original genetic characteristics and highly restore physiological activities in vivo, making them irreplaceable core experimental materials for high-precision basic research and preclinical studies. Compared with immortalized cell lines, primary cells feature high isolation and production thresholds as well as strict quality control standards. However, uneven...

Read more

Vicore Pharma Appoints Rob Slack as Chief Scientific Officer

July 6, 2026 2:20 AM

Vicore Pharma Holding (STO:VICO) - Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science and joins from GSK, where he served as Vice President and Head of Respiratory Biology Stockholm, Sweden & Cambridge, Mass., July 6, 2026 - Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type...

Read more

Raymond Rodriguez-Torres Appointed President of First Ascent Biomedical

July 2, 2026 2:00 PM

First Ascent Biomedical announced that its Board of Directors has unanimously appointed Raymond Rodriguez-Torres as President, marking a significant milestone in the company's mission to advance Functional Precision Oncology (FPO) and transform cancer treatment through biology-driven, patient-specific decision support. Bringing more than two decades of nursing, biotechnology and pharmaceuticals leadership experience, Rodriguez-Torres joins First...

Read more

CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

July 2, 2026 1:05 PM

Emerging Growth Research today issued a flash report on OSR Health, Inc. (Nasdaq:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains...

Read more

Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

July 2, 2026 9:00 AM

Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains...

Read more

Alligator Announces First Patient Dosed in Investigator-Initiated Study of Intratumoral Mitazalimab in Early-Stage Breast Cancer

July 2, 2026 4:45 AM

Alligator Bioscience (STO:ATORX) First patient dosed in an investigator-initiated trial evaluating intratumoral mitazalimab, with or without intratumoral nivolumab Study evaluates how local CD40 activation affects the tumor microenvironment ahead of surgery to inform future clinical development Trial conducted at an Ivy League university in the United States Lund, Sweden - 2 July 2026 - Alligator Bioscience (Nasdaq Stockholm: ATORX), a...

Read more

Vicore Pharma to Commence Trading in the United States on the Nasdaq Stock Market

July 1, 2026 4:50 PM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that American Depositary Shares (ADSs) representing its common shares will commence trading on The Nasdaq Capital Market (Nasdaq US) on July 2, 2026, under the ticker symbol VCRE. Each ADS represents 10 common shares of the company....

Read more

Fast, Accurate and Stable: Cloud-Clone Takes the Lead in the Immunofluorescence Technology Sector Through Core Competitive Strength

July 1, 2026 10:00 AM

In the wave of precision medicine development and accelerated iteration of life science technology, immunofluorescence (IF) technology has become a core supporting tool in medical diagnostics, basic scientific research and drug development, thanks to its unique advantages including high specificity, high sensitivity, and in-situ precise localization and quantification. However, common pain points such as signal deviation in scientific...

Read more

Faron Pharmaceuticals Ltd: Grant of Options

July 1, 2026 6:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's board has confirmed the grant of a total of 2,173,000 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2026. The Options have been allocated under the Share Option Plan 2026 and are exercisable after 1 June 2029, vesting...

Read more

Biovica Granted Japanese Patent for Immuno-Oncology

July 1, 2026 3:30 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced that the Japanese Patent Office has granted a new patent covering the use of TKa in relation to immune checkpoint inhibitor treatment in cancer patients. The granting expands Biovica's patent protection in immuno-oncology from Europe to Japan, adding another important oncology market to the company's growing...

Read more

Update on 2026 Outlook and Company Progress

July 1, 2026 2:50 AM

FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) , a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an update on the 2026 Outlook and ongoing progress. As part of this update, FluoGuide has refined timing of some milestones. There are no changes to the overall development. "FluoGuide has made substantial progress during the first half of 2026. We are proud having reported positive results on all...

Read more

AAA Biotech Expands Global Authorized Distributor Network to Improve Access to High-Quality Research Reagents

June 30, 2026 8:00 AM

AAA Biotech, a supplier of high-quality research reagents for life science applications, today announced the expansion of its global authorized distributor network aimed at improving access to antibodies, recombinant proteins, and ELISA kits for researchers across key international markets. This expansion strengthens the company's commitment to supporting biomedical research by ensuring faster and more reliable access to critical laboratory...

Read more

Correction: Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI

June 30, 2026 7:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announces that it has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, Inc., announced in May 2025. Under the agreement, Tempus was intended to offer DiviTum® TKa as part of its diagnostic portfolio to its network of oncologists in the United States. The collaboration did not progress to...

Read more

Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI

June 30, 2026 7:00 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announces that it has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, Inc., announced in May 2025. Under the agreement, Tempus was intended to offer DiviTum® TKa as part of its diagnostic portfolio to its network of oncologists in the United States. The collaboration did not progress to...

Read more

The Next Era of Automated Super-Resolution Discovery

June 30, 2026 7:00 AM

Some of the most critical biology happens below 100 nanometers, including receptor organization, antibody binding, and therapeutic nanoparticle characterization. Traditional platforms cannot reliably resolve features at this scale, leaving these critical molecular interactions invisible. Super-resolution microscopy overcomes this limitation, enabling scientists to visualize biology with remarkable precision and answer questions that conventional...

Read more

Biovica International AB - Annual Report for The Financial Year 2025/2026 Published

June 30, 2026 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Annual Report for the financial year 2025/2026 for Biovica international AB is published today on our website. Please see link below. Contact Theis Kipling, CEO Telefon: +46 (0) 76 666 36 52 E-post: [email protected] Anders Morén, CFO Phone: +46 73 125 92 46 E-mail: [email protected] Biovica - Treatment decisions with greater confidence Biovica develops and...

Read more